ID

35508

Descripción

The Study of CIK Plus S-1 and Bevacizumab as Maintenance Treatment for Patients With Advanced Colorectal Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02487992

Link

https://clinicaltrials.gov/show/NCT02487992

Palabras clave

Versiones (1)
  1. 6/3/19 6/3/19 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

6 de marzo de 2019

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Colorectal Neoplasms NCT02487992

Inglés

Eligibility Colorectal Neoplasms NCT02487992

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients who can accept curative operations 18-70 years old
Descripción

Curative Surgery Acceptable | Age

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1511562
UMLS CUI [1,2]
C1879533
UMLS CUI [2]
C0001779
histologically confirmed with colorectal cancer at stage ⅳ
Descripción

Colorectal Carcinoma TNM clinical staging

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0009402
UMLS CUI [1,2]
C3258246
patients who can accept oral drugs;
Descripción

Oral medication Acceptable

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0175795
UMLS CUI [1,2]
C1879533
eastern cooperative oncology group (ecog) performance status was 0 - 1.
Descripción

ECOG performance status

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1520224
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
hemoglobin＜8.0 g/dl,white blood cell ＜3 x 10^9/l;platelet count ＜75 x 10^9/l; alanine aminotransferase, glutamic-oxalacetic transaminase, blood urine nitrogen and creatinine more than normal limits on 3.0 times
Descripción

Hemoglobin measurement | White Blood Cell Count procedure | Platelet Count measurement | Alanine aminotransferase increased | Aspartate aminotransferase increased | Blood urea increased | Serum creatinine raised

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0518015
UMLS CUI [2]
C0023508
UMLS CUI [3]
C0032181
UMLS CUI [4]
C0151905
UMLS CUI [5]
C0151904
UMLS CUI [6]
C0151539
UMLS CUI [7]
C0700225
known or suspected allergy to the investigational agent or any agent given in association with this trial
Descripción

Hypersensitivity Investigational New Drugs | Hypersensitivity Pharmaceutical Preparations Clinical Trial | Hypersensitivity Suspected Investigational New Drugs | Hypersensitivity Suspected Pharmaceutical Preparations Clinical Trial

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0013230
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0013227
UMLS CUI [2,3]
C0008976
UMLS CUI [3,1]
C0020517
UMLS CUI [3,2]
C0750491
UMLS CUI [3,3]
C0013230
UMLS CUI [4,1]
C0020517
UMLS CUI [4,2]
C0750491
UMLS CUI [4,3]
C0013227
UMLS CUI [4,4]
C0008976
pregnant or lactating patients
Descripción

Pregnancy | Breast Feeding

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
known history of human immunodeficiency virus (hiv), hepatitis c virus (hcv) or treponemapallidun (tp) infection
Descripción

HIV Infection | Hepatitis C | Syphilis

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0019693
UMLS CUI [2]
C0019196
UMLS CUI [3]
C0039128
patients who are suffering from serious autoimmune disease
Descripción

Autoimmune Disease Serious

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0004364
UMLS CUI [1,2]
C0205404
patients who had used long time or are using immunosuppressant
Descripción

Immunosuppressive Agents

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021081
patients who had active infection
Descripción

Communicable Disease

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0009450
patients who are suffering from serious organ dysfunction
Descripción

Organ dysfunction Serious

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0349410
UMLS CUI [1,2]
C0205404
patients who are suffering from other cancer
Descripción

Cancer Other

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1707251
other situations that the researchers considered unsuitable for this study.
Descripción

Social situation Inappropriate Clinical Trial

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0748872
UMLS CUI [1,2]
C1548788
UMLS CUI [1,3]
C0008976
Volver a la parte superior de la página

Similar models

Eligibility Colorectal Neoplasms NCT02487992

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Curative Surgery Acceptable | Age
Item
patients who can accept curative operations 18-70 years old
boolean
C1511562 (UMLS CUI [1,1])
C1879533 (UMLS CUI [1,2])
C0001779 (UMLS CUI [2])
Colorectal Carcinoma TNM clinical staging
Item
histologically confirmed with colorectal cancer at stage ⅳ
boolean
C0009402 (UMLS CUI [1,1])
C3258246 (UMLS CUI [1,2])
Oral medication Acceptable
Item
patients who can accept oral drugs;
boolean
C0175795 (UMLS CUI [1,1])
C1879533 (UMLS CUI [1,2])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status was 0 - 1.
boolean
C1520224 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Hemoglobin measurement | White Blood Cell Count procedure | Platelet Count measurement | Alanine aminotransferase increased | Aspartate aminotransferase increased | Blood urea increased | Serum creatinine raised
Item
hemoglobin＜8.0 g/dl,white blood cell ＜3 x 10^9/l;platelet count ＜75 x 10^9/l; alanine aminotransferase, glutamic-oxalacetic transaminase, blood urine nitrogen and creatinine more than normal limits on 3.0 times
boolean
C0518015 (UMLS CUI [1])
C0023508 (UMLS CUI [2])
C0032181 (UMLS CUI [3])
C0151905 (UMLS CUI [4])
C0151904 (UMLS CUI [5])
C0151539 (UMLS CUI [6])
C0700225 (UMLS CUI [7])
Hypersensitivity Investigational New Drugs | Hypersensitivity Pharmaceutical Preparations Clinical Trial | Hypersensitivity Suspected Investigational New Drugs | Hypersensitivity Suspected Pharmaceutical Preparations Clinical Trial
Item
known or suspected allergy to the investigational agent or any agent given in association with this trial
boolean
C0020517 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0013227 (UMLS CUI [2,2])
C0008976 (UMLS CUI [2,3])
C0020517 (UMLS CUI [3,1])
C0750491 (UMLS CUI [3,2])
C0013230 (UMLS CUI [3,3])
C0020517 (UMLS CUI [4,1])
C0750491 (UMLS CUI [4,2])
C0013227 (UMLS CUI [4,3])
C0008976 (UMLS CUI [4,4])
Pregnancy | Breast Feeding
Item
pregnant or lactating patients
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
HIV Infection | Hepatitis C | Syphilis
Item
known history of human immunodeficiency virus (hiv), hepatitis c virus (hcv) or treponemapallidun (tp) infection
boolean
C0019693 (UMLS CUI [1])
C0019196 (UMLS CUI [2])
C0039128 (UMLS CUI [3])
Autoimmune Disease Serious
Item
patients who are suffering from serious autoimmune disease
boolean
C0004364 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
Immunosuppressive Agents
Item
patients who had used long time or are using immunosuppressant
boolean
C0021081 (UMLS CUI [1])
Communicable Disease
Item
patients who had active infection
boolean
C0009450 (UMLS CUI [1])
Organ dysfunction Serious
Item
patients who are suffering from serious organ dysfunction
boolean
C0349410 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
Cancer Other
Item
patients who are suffering from other cancer
boolean
C1707251 (UMLS CUI [1])
Social situation Inappropriate Clinical Trial
Item
other situations that the researchers considered unsuitable for this study.
boolean
C0748872 (UMLS CUI [1,1])
C1548788 (UMLS CUI [1,2])
C0008976 (UMLS CUI [1,3])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial